Influences of tirofiban on safety and short-term prognosis in patients with acute ST-segment elevation myocardial infarction
ZHU Jian-bing
WANG Jin
ZHOU Jun
GUO Hua
YU Xiao-wen
ZHANG Jun-feng
Abstract：Objective To investigate the safety and short-term prognosis of PCI assisted with tirofiban in the patients with acute ST-segment elevation myocardial infarction (STEMI). Methods The patients (n=468) with emergency PCI were chosen from Dec. 2008 to Jun. 2012, and divided into tirofiban group (n=351) and control group (n=117) according. The safety indexes (severe bleeding, mild bleeding and thrombocytopenia) were analyzed by using Kaplan-Meier and Cox proportional hazard models in the patients during hospitalization. The incidence of major adverse cardiovascular events (MACE, death, reinfarction and target vessel revascularization) was observed respectively 30 d and 90 d after the surgery. Results The safety indexes had no statistical difference between tirofiban group and control group (P>0.05). The incidence of MACE was lower in tirofiban group than that in control group after 30 d (7.98%vs. 16.24%, P=0.01) and 90 d (8.55%vs. 19.66%, P=0.001). The survival analysis of Kaplan-Meier showed that survival rate without MACE was significantly higher in tirofiban group than that in control group after 30 d (Log Rank=7.977, P=0.005) and 90 d (Log Rank=12.371, P<0.001). Cox proportional hazard models showed that tirofiban reduced the incidence of MACE after 30 d (HR=0.443, 95%CI:0.247-0793, P=0.006) and 90 d (HR=0.391, 95%CI:0.227-0.674, P=0.001). Conclusion Tirofiban can improve the short-term prognosis with higher safety in STEMI patients with direct PCI.
Keywords：TirofibanAcute myocardial infarctionPrognosisPercutaneous coronary intervention
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 40-43 )